Nektar Therapeutics (NKTR)
39.22
+2.58
(+7.04%)
USD |
NASDAQ |
Oct 20, 16:00
39.16
-0.06
(-0.17%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (TTM) : 131.74M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 131.74M |
| March 31, 2026 | 122.50M |
| December 31, 2025 | 117.30M |
| September 30, 2025 | 116.36M |
| June 30, 2025 | 124.14M |
| March 31, 2025 | 123.98M |
| December 31, 2024 | 120.91M |
| September 30, 2024 | 122.10M |
| June 30, 2024 | 111.14M |
| March 31, 2024 | 111.10M |
| December 31, 2023 | 114.16M |
| September 30, 2023 | 118.96M |
| June 30, 2023 | 128.48M |
| March 31, 2023 | 141.54M |
| December 31, 2022 | 218.32M |
| September 30, 2022 | 283.20M |
| June 30, 2022 | 353.34M |
| March 31, 2022 | 411.92M |
| December 31, 2021 | 400.27M |
| September 30, 2021 | 403.38M |
| June 30, 2021 | 400.17M |
| March 31, 2021 | 395.30M |
| December 31, 2020 | 408.68M |
| September 30, 2020 | 416.32M |
| June 30, 2020 | 414.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 425.09M |
| December 31, 2019 | 434.57M |
| September 30, 2019 | 433.08M |
| June 30, 2019 | 436.93M |
| March 31, 2019 | 418.58M |
| December 31, 2018 | 399.54M |
| September 30, 2018 | 372.08M |
| June 30, 2018 | 334.90M |
| March 31, 2018 | 306.83M |
| December 31, 2017 | 268.46M |
| September 30, 2017 | 237.26M |
| June 30, 2017 | 223.50M |
| March 31, 2017 | 215.59M |
| December 31, 2016 | 203.80M |
| September 30, 2016 | 200.70M |
| June 30, 2016 | 191.98M |
| March 31, 2016 | 185.04M |
| December 31, 2015 | 182.79M |
| September 30, 2015 | 174.15M |
| June 30, 2015 | 165.12M |
| March 31, 2015 | 156.41M |
| December 31, 2014 | 147.73M |
| September 30, 2014 | 146.19M |
| June 30, 2014 | 155.90M |
| March 31, 2014 | 171.43M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly & Co. | 14.60B |
| Inovio Pharmaceuticals, Inc. | 47.16M |
| Tonix Pharmaceuticals Holding Corp. | 63.86M |
| Capricor Therapeutics, Inc. | 98.66M |
| Kyntra Bio, Inc. | 22.86M |